Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Express Scripts
Baxter

Last Updated: May 28, 2022

Investigational Drug Information for ARN-509


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for ARN-509?

ARN-509 is an investigational drug.

There have been 47 clinical trials for ARN-509. The most recent clinical trial was a Phase 2 trial, which was initiated on December 17th 2019.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Adenocarcinoma, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Janssen Scientific Affairs, LLC, and Aragon Pharmaceuticals, Inc.

There are one hundred and fifty-seven US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for ARN-509
TitleSponsorPhase
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerM.D. Anderson Cancer CenterPhase 2
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate GlandNational Cancer Institute (NCI)Phase 2
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNational Cancer Institute (NCI)Phase 3

See all ARN-509 clinical trials

Clinical Trial Summary for ARN-509

Top disease conditions for ARN-509
Top clinical trial sponsors for ARN-509

See all ARN-509 clinical trials

US Patents for ARN-509

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ARN-509 See Plans and Pricing Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) See Plans and Pricing
ARN-509 See Plans and Pricing Selective androgen receptor degrader (SARD) ligands and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) GTX, INC. (Memphis, TN) See Plans and Pricing
ARN-509 See Plans and Pricing Inhibitors of ACK1/TNK2 tyrosine kinase H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) See Plans and Pricing
ARN-509 See Plans and Pricing Macrocylic pyrimidine derivatives Janssen Pharmaceutica NV (Beerse, BE) See Plans and Pricing
ARN-509 See Plans and Pricing Androgen receptor modulators and uses thereof Aragon Pharmaceuticals, Inc. (San Diego, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ARN-509

Drugname Country Document Number Estimated Expiration Related US Patent
ARN-509 Argentina AR107432 2036-01-11 See Plans and Pricing
ARN-509 Australia AU2017207268 2036-01-11 See Plans and Pricing
ARN-509 Australia AU2019203280 2036-01-11 See Plans and Pricing
ARN-509 Australia AU2021201018 2036-01-11 See Plans and Pricing
ARN-509 Brazil BR112018014015 2036-01-11 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.